In HFrEF patients, NT-pro or BNP-guided therapy compared with symptom-guided therapy resulted in lower mortality (HR, 0.78, 95% CI, 0.62–0.97, p = 0.03) and fewer HF admissions (HR, 0.80, 95% CI, 0.67–0.97, p = 0.02), whereas in HFpEF patients, renal failure provided the strongest interaction. The gene discussed is NPPB; the disease is Renal insufficiency.